Characteristics and reference ranges of Insulin-Like Growth Factor-I measured with a commercially available immunoassay in 724 healthy adult Caucasians

被引:11
作者
Andreassen, Mikkel [1 ]
Nielsen, Kaspar [2 ]
Raymond, Ilan [3 ]
Kristensen, Lars Ostergaard
Faber, Jens
机构
[1] Univ Copenhagen, Dept Endocrinol, Herlev Hosp, Lab Endocrinol 5404, DK-2730 Herlev, Denmark
[2] Aalborg Hosp, Reg Ctr Blood Transfus & Clin Immunol, Aalborg, Denmark
[3] Univ Copenhagen, Dept Cariol & Endodontol, Frederiksberg Hosp, DK-1168 Copenhagen, Denmark
关键词
Growth hormone; Insulin-like growth factor 1; reference ranges; assay validation; Enzyme-Linked Immunosorbent Assay; BINDING PROTEIN-3 IGFBP-3; FREE IGF-I; SERUM; ASSAYS; SEX; AGE; POPULATION; VALUES; WOMEN; MEN;
D O I
10.3109/00365510903165477
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background and Objective: Measurements of Insulin-Like Growth Factor-I (IGF-I) play a pivotal role in the evaluation of the growth hormone-IGF-I axis. Due to assay variation IGF-I reference ranges are assay specific. We provide serum IGF-I reference ranges for adult men and women obtained by a commercially available assay. Method: IGF-I was measured by an enzyme-linked immunosorbent assay (R&D Systems). Assay precision was evaluated in low, medium and high IGF-I pools and in single samples from outpatients. The reference ranges were obtained in 724 healthy Caucasians, mean age 48 years (range 19-91). Results: IGF-I was measured higher in serum compared to plasma samples (p < 0.001, R-2 = 0.96). To convert EDTA plasma values to serum values a factor of 1.22 was calculated. The intraassay coefficients of variation (CV) for the low: 56.4 +/- 2.7 ng/mL, medium: 179.7 +/- 5.9 ng/mL and high pool: 445.61 +/- 3.2 ng/mL (mean 1SD) were 5, 3 and 3%. Interassays CVs for the low, medium and high pool varied between 7-10, 5-7, and 6-9%. Reproducibility between 4 different lots showed a intraclass CV of 0.99 (95% CI 0.98-0.96). Logarithmically transformed IGF-I levels were linearly associated with age with a 13% reduction in IGF-I per decade in females and 11% in males. Conclusion: We have provided IGF-I reference ranges obtained by an assay that showed variations and reproducibility that was considered of sufficient high quality for clinical and scientific use.
引用
收藏
页码:880 / 885
页数:6
相关论文
共 19 条
[11]   SERUM INSULIN-LIKE GROWTH-FACTOR-I IN A RANDOM-POPULATION SAMPLE OF MEN AND WOMEN - RELATION TO AGE, SEX, SMOKING-HABITS, COFFEE CONSUMPTION AND PHYSICAL-ACTIVITY, BLOOD-PRESSURE AND CONCENTRATIONS OF PLASMA-LIPIDS, FIBRINOGEN, PARATHYROID-HORMONE AND OSTEOCALCIN [J].
LANDINWILHELMSEN, K ;
WILHELMSEN, L ;
LAPPAS, G ;
ROSEN, T ;
LINDSTEDT, G ;
LUNDBERG, PA ;
BENGTSSON, BA .
CLINICAL ENDOCRINOLOGY, 1994, 41 (03) :351-357
[12]   Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: Comparison of four immunoassays [J].
Massart, C. ;
Poirier, J. Y. .
CLINICA CHIMICA ACTA, 2006, 373 (1-2) :176-179
[13]   Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men [J].
Münzer, T ;
Rosen, CJ ;
Harman, SM ;
Pabst, KM ;
St Clair, C ;
Sorkin, JD ;
Blackman, MR .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2006, 290 (05) :E1006-E1013
[14]   Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice [J].
Pokrajac, A. ;
Wark, G. ;
Ellis, A. R. ;
Wear, J. ;
Wieringa, G. E. ;
Trainer, P. J. .
CLINICAL ENDOCRINOLOGY, 2007, 67 (01) :65-70
[15]   Reference levels of insulin-like growth factor I in the serum of healthy adults:: Comparison of four immunoassays [J].
Ranke, MB ;
Osterziel, KJ ;
Schweizer, R ;
Schuett, B ;
Weber, K ;
Röbbel, P ;
Vornwald, A ;
Blumenstock, G ;
Elmlinger, MW .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (10) :1329-1334
[16]   How should insulin-like growth factor I be measured?: A consensus statement [J].
Ranke, MB ;
Feldt-Rasmussen, U ;
Bang, P ;
Baxter, RC ;
Camacho-Hübner, C ;
Clemmons, DR ;
Juul, A ;
Orskove, H ;
Strasburger, CJ .
HORMONE RESEARCH, 2001, 55 :106-109
[17]  
Raymond Ilan, 2002, HeartDrug, V2, P167, DOI 10.1159/000065944
[18]  
Yu H, 1999, J CLIN LAB ANAL, V13, P166, DOI 10.1002/(SICI)1098-2825(1999)13:4<166::AID-JCLA5>3.0.CO
[19]  
2-X